Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA as Adjuvant Therapy for Acne Vulgaris Mild to Moderate

Status: Unknown
Location: See all (5) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This clinical study will compare the effectivity and safety of combination cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad, and Zinc PCA as adjuvant therapy for acne vulgaris patients. These combination cream will be tested by mild to moderate acne vulgaris patients. Participants will be female patients aged 15-50 years old and divided into three groups. The control group (Group 1) will use Adapalene 0.1% cream only every night. Group 2 will use Adapalene 0.1% cream intermittently every two nights and the combination cream every morning. Group 3 will use Adapalene 0.1% cream every night and the combination cream every morning.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 15
Maximum Age: 50
Healthy Volunteers: t
View:

• Female aged 15 - 50 years

• Mild and moderate acne vulgaris according to IAEM and GEA.

• Patients are willing to participate in the study until it is finished.

Locations
Other Locations
Indonesia
Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
Jakarta
Rumah Sakit Umum Pusat Cipto Mangunkusumo
Jakarta
Rumah Sakit Umum Daerah Saiful Anwar
Malang
Rumah Sakit Umum Pusat Dr. M. Djamil
Padang
Rumah Sakit Umum Daerah Dr. Moewardi
Surakarta
Time Frame
Start Date: 2022-08-01
Completion Date: 2023-05-01
Participants
Target number of participants: 284
Treatments
Experimental: Combination Cream Group
Group 2 will use Adapalene 0.1% cream intermittently every two nights and the combination cream every morning. Group 3 will use Adapalene 0.1% cream every night and the combination cream every morning. Subjects were evaluated on day 28 and day 56.
Other: Adapalene 0,1% cream
The control group (Group 1) will use Adapalene 0.1% cream only every night. Subjects were evaluated on day 28 and day 56.
Related Therapeutic Areas
Sponsors
Leads: Dr.dr.Irma Bernadette, SpKK (K)

This content was sourced from clinicaltrials.gov